Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2017 May 27

PMID 28548075

Citations 22

Authors

Carminia Maria Della Corte

Morena Fasano

Federica Papaccio

Fortunato Ciardiello

Floriana Morgillo

Affiliations

Soon will be listed here.

Abstract

The Hepatocyte growth factor (HGF)-mesenchymal-epithelial transition (MET) pathway is deregulated in several cancers and is associated with aggressive phenotype and worse prognosis. MET, a tyrosine kinase receptor activated by HGF, plays a physiological role in embryogenesis, promoting cell growth, survival and motility. HGF-MET aberrant activation in tumorigenesis acts through various mechanisms: paracrine/autocrine HGF production, MET overexpression, MET germ-line and sporadic mutations and cross-talk with other growth factor receptors. In addition, MET activation could represent a mechanism of escape from other targeted therapies, through receptor amplification or over-stimulation by the ligand, as demonstrated in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) models with acquired resistance to epidermal growth factor receptor (EGFR) inhibitors and also in models of melanoma resistant to the BRAF inhibitor vemurafenib. As a consequence, a lot of molecules targeting MET signaling are under clinical investigation as single agent or in combination with other targeted drugs. Patient selection, based on MET expression on tumor samples (eventually, by re-biopsy of new metastatic sites), and pharmacokinetic/pharmacodynamic markers are needed. Authors review the latest data on the role of MET and the molecular mechanism underlying primary or acquired resistance to biological agents, focusing on NSCLC, CRC and melanoma.

Citing Articles

A Novel Digital PCR Assay for Accurate Detection and Differentiation of Focal and Non-Focal Subtypes of Mesenchymal-Epithelial Transition () Gene Amplification in Lung Cancer.

Shek R, Li P, Leung S, Chu H, Hioe F, Tang V Cancers (Basel). 2025; 17(5).

PMID: 40075658 PMC: 11898889. DOI: 10.3390/cancers17050811.

Hepatocyte growth factor promotes melanoma metastasis through ubiquitin-specific peptidase 22-mediated integrins upregulation.

Gao Q, Li N, Pan Y, Chu P, Zhou Y, Jia H Cancer Lett. 2024; 604:217196.

PMID: 39222676 PMC: 11542356. DOI: 10.1016/j.canlet.2024.217196.

Deafness DFNB128 Associated with a Recessive Variant of Human Recapitulates Hearing Loss of -Deficient Mice.

Faridi R, Yousaf R, Inagaki S, Olszewski R, Gu S, Morell R Genes (Basel). 2024; 15(7).

PMID: 39062623 PMC: 11276321. DOI: 10.3390/genes15070845.

Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling.

Albadari N, Xie Y, Li W Front Pharmacol. 2024; 14:1340401.

PMID: 38269272 PMC: 10806212. DOI: 10.3389/fphar.2023.1340401.

MET Receptor Tyrosine Kinase Inhibition Reduces Interferon-Gamma (IFN-γ)-Stimulated PD-L1 Expression through the STAT3 Pathway in Melanoma Cells.

Song K, Han Y, Roehrich H, Brown M, Torres-Cabala C, Giubellino A Cancers (Basel). 2023; 15(13).

PMID: 37444518 PMC: 10340457. DOI: 10.3390/cancers15133408.

References

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C . A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2012; 1(6):508-23. DOI: 10.1158/2159-8290.CD-11-0109. View

Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian Z, Du J . Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487(7408):500-4. PMC: 3711467. DOI: 10.1038/nature11183. View

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

Dummer R, Flaherty K . Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol. 2012; 24(2):150-4. DOI: 10.1097/CCO.0b013e32834fca92. View

Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P . Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One. 2009; 4(10):e7287. PMC: 2750753. DOI: 10.1371/journal.pone.0007287. View

Sharma A, Shah S, Illum H, Dowell J . Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs. 2012; 72(17):2207-22. DOI: 10.2165/11640870-000000000-00000. View

Kim Y, Choi J, Seo J, Song J, Lee S, Kwon M . MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. Int J Cancer. 2014; 134(10):2424-36. DOI: 10.1002/ijc.28566. View

Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y, Ngankeu A . EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 2011; 18(1):74-82. PMC: 3467100. DOI: 10.1038/nm.2577. View

Trusolino L, Comoglio P . Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2002; 2(4):289-300. DOI: 10.1038/nrc779. View

10.

Schmidt L, Duh F, Chen F, Kishida T, Glenn G, Choyke P . Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997; 16(1):68-73. DOI: 10.1038/ng0597-68. View

11.

Hsiao S, Liu H, Lee H, Lin C, Chen W, Wu Z . Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders. PLoS One. 2013; 8(12):e83266. PMC: 3871587. DOI: 10.1371/journal.pone.0083266. View

12.

Park S, Choi Y, Sung C, An J, Seo J, Ahn M . High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol. 2011; 27(2):197-207. DOI: 10.14670/HH-27.197. View

13.

Scagliotti G, Novello S, Schiller J, Hirsh V, Sequist L, Soria J . Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer. 2012; 13(5):391-5. DOI: 10.1016/j.cllc.2012.01.003. View

14.

Lengyel E, Prechtel D, Resau J, Gauger K, Welk A, Lindemann K . C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2004; 113(4):678-82. DOI: 10.1002/ijc.20598. View

15.

Herrera L, El-Hefnawy T, Queiroz de Oliveira P, Raja S, Finkelstein S, Gooding W . The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia. 2005; 7(1):75-84. PMC: 1490312. DOI: 10.1593/neo.04367. View

16.

Nakamura T, Sakai K, Nakamura T, Matsumoto K . Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol. 2011; 26 Suppl 1:188-202. DOI: 10.1111/j.1440-1746.2010.06549.x. View

17.

Fischer O, Giordano S, Comoglio P, Ullrich A . Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem. 2004; 279(28):28970-8. DOI: 10.1074/jbc.M402508200. View

18.

Bauer T, Somcio R, Fan F, Liu W, Johnson M, Lesslie D . Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther. 2006; 5(7):1676-82. DOI: 10.1158/1535-7163.MCT-05-0175. View

19.

Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P . Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia. 2012; 13(12):1132-42. PMC: 3257188. DOI: 10.1593/neo.111102. View

20.

La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C . Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. PLoS One. 2013; 8(10):e78656. PMC: 3805532. DOI: 10.1371/journal.pone.0078656. View